Lymph node micrometastases in initial stage cervical cancer and tumoral recurrence. Issue 1 (19th December 2015)

• Record Type: Journal Article
• Authors: Colturato, Leandro F.; Signorini Filho, Roney C.; Fernandes, Raquel C.M.; Gebrim, Luiz H.; Oliani, Antônio H.
• Is Part Of: International journal of gynaecology and obstetrics. Volume 133:Issue 1(2016:Apr.)
• Page Start: 69
• Page End: 75
• Publication Date: 2015-12-19
• Subjects: Gynecologic surgical procedures -- Keratins -- Local -- Neoplasm micrometastasis -- Neoplasm recurrence -- Uterine cervical neoplasms; Gynecology -- Periodicals; Obstetrics -- Periodicals; Electronic journals; 618
• DOI: 10.1016/j.ijgo.2015.08.019
• Languages: English
• ISSNs: 0020-7292

Abstract

Abstract: Objective: To evaluate the prevalence of micrometastases in lymph node tissue of patients with stage Ib1–IIA cervical cancer, the correlation of micrometastases with tumor recurrence and survival, and the expression of D2‐40 in the primary tumor of patients with recurrence and/or micrometastases and its correlation with histopathologic findings. Methods: In a retrospective study, the medical records of all patients with cervical cancer treated at a hospital in São Paulo, Brazil, between 2001 and 2007 were reviewed. Patients with no lymph node metastases and treated with radical hysterectomy without adjuvant treatment were included. Tumor sections were reviewed and lymph nodes were analyzed with AE1/AE3. Patients with and without recurrence were compared. The presence of lymph node micrometastasis or isolated tumor cells was also evaluated. Results: Of the 83 patients evaluated, 15 (18%) had recurrence. Significant differences between patients with and without recurrence were observed with regard to tumor greatest axis, clinical stage, number of micrometastases, and negative lymph nodes ( P ≤ 0.04). Lymph node micrometastases and isolated tumor cells were significantly different for a stromal invasion depth greater than 2/3 ( P = 0.046). Conclusion: The presence of lymph node micrometastases is an important risk factor for tumor recurrence. These patients should be considered eligible for adjuvant radiochemotherapy treatment.